IL-22 Is an Intestinal Stem Cell Growth Factor, and IL-22 Administration in Vivo Reduces Morbidity and Mortality in Murine GvHD
Caroline A. Lindemans(University Medical Center Utrecht), Alan M. Hanash(Memorial Sloan Kettering Cancer Center), Gillian Lawrence(Memorial Sloan Kettering Cancer Center), Margaret O'Connor(Memorial Sloan Kettering Cancer Center), Jarrod A. Dudakov(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Juliet Ivanov(Memorial Sloan Kettering Cancer Center), Robert R. Jenq(City Of Hope National Medical Center), Odette M. Smith(Memorial Sloan Kettering Cancer Center), Richard Kolesnick(Memorial Sloan Kettering Cancer Center), M. Laura Martín(Cornell University), Natalie Luo(Memorial Sloan Kettering Cancer Center), Anna Mertelsmann(University of Zurich), Enrico Velardi(Bambino Gesù Children's Hospital), Chen Liu(Kunming University of Science and Technology), Lauren Young(Memorial Sloan Kettering Cancer Center), Guoqiang Hua(Inserm), Marcel R.M. van den Brink(City Of Hope National Medical Center)
Cited by 2
Related Papers
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Genomic analysis identifies association of <i>Fusobacterium</i> with colorectal carcinoma
|Genome Research|2011|2k
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
|New England Journal of Medicine|2012|1.9k